Hemab ApS

https://www.hemab.com

Twitter: @hemab_tx

LinkedIn: https://www.linkedin.com/company/hemabaps

Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in the US and Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company's strategic guidance, Hemab 1-2-5TM, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with Factor VII Deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and other serious disorders. *

	Start	2019-01-01 established (s-off)
	Industry	therapeutic antibody
	Industry 2	haemostat
	Person	Faber, Johan H. (Hemab 202012 CEO + Co-Founder)
	Person 2	Petersen, Jørgen Søberg (Novo Group 201907 Venture Partner at Novo Ventures)

	Region	København (Copenhagen)
	Country	Denmark
	Street	3 Ole Maaløes Vej
	City	2200 København
		Address record changed: 2023-02-22

Basic data	Employees	n. a.

		* Document for »About Section«: Hemab ApS. (2/21/23). "Press Release: Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders". Copenhagen & Boston, MA.

		Record changed: 2023-07-10